Sign in to view content

Comparison of CRISPR-based Genome Editing of VEGF-A as Treatment Strategy for Choroidal Neovascularization

Glenn C. Yiu, MD, PhD

Video
Published 2019

Related

RGX-314 for Neovascular AMD: Ongoing Phase I/IIa Results for Cohorts 1-5
Arshad M. Khanani, MD, MA, FASRS
Annual Meeting Talks
2020
Assessing Commercially Available Cell Therapies for Retinal Disease in the U.S.
Ajay E Kuriyan, MD, MS
Daniel Simhaee, MD
Updates from the Field
2018
Efficacy and Safety of Multiwavelength Photobiomodulation in Dry Age-Related Macular Degeneration Using the LumiThera Valeda System (LIGHTSITE III Interim Analysis)
Richard B. Rosen, MD, DSc(Hon), FACS, FASRS, FARVO
Updates from the Field
2022

Category: AMD-Neovascular

See more